A new beta-adrenergic blocking drug in hypertension. A report from the General Practitioner Research Group.
It was concluded that acebutolol alone, in the doses given over the periods for which it was used, produced a modest hypotensive effect, which was not quite so great as that produced by bendrofluazide alone, although the differences are not statistically significant. On the other hand, the combination of the two drugs produced both a more rapid and more effective hypotensive action, which was more than might be expected by simple summation of the effects of the two drugs together. It would be seen that, in view of the virtual absence of side-effects, the combination of acebutolol with bendrofluazide may be particularly effective in the treatment of hypertension.
D000070:Acebutolol / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001539:Bendroflumethiazide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012075:Remission, Spontaneous
D001539:Bendroflumethiazide; D000070:Acebutolol